U.K. cost watchdogs nix Dendreon's Provenge; GSK's Slaoui joins IAVI board;

> The U.K.'s cost watchdogs have deemed Dendreon's ($DNDN) cancer vaccine Provenge too expensive for coverage on England's National Health Service. Report

> GlaxoSmithKline ($GSK) Global Vaccines Chairman Moncef Slaoui has joined the board of directors of the International AIDS Vaccine Initiative (IAVI). Release

> Sanofi Pasteur is planning a large-scale renovation project that will include construction of a new quality control building, set to begin early this year. Report

> San Diego, CA-based biotech Polynoma has launched a Phase III trial of its melanoma vaccine candidate. More

And Finally... Influenza vaccination may protect against Guillain-Barre syndrome, a new study suggests. More (reg. req.)

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.